56 research outputs found
Electrochemical Behavior of Al–Al9Co2 Alloys in Sulfuric Acid
Al–Co alloys of various Co contents (2–20 wt.% Co) were fabricated by vacuum arc melting (VAM) with the scope to investigate the influence of cobalt on the microstructure and corrosion resistance of Al in 1 M H2SO4. The obtained microstructures were directional, consisting of Al9Co2 platelets (grown to coarse acicular plates as the Co content increased) uniformly dispersed in an Al-matrix. Alloying Al with Co did not decrease the rate of uniform corrosion of Al but it considerably increased its passivation ability. Moreover, all Al–Co alloys displayed lower uniform corrosion rate and notably higher passivation ability than market leading Al-alloys. The underlying mechanisms during anodic polarization in 1 M H2SO4 were identified and correlated with the microstructure. High Co content alloys (7–20 wt.% Co) presented superior passivation ability in 1 M H2SO4 as compared to the low Co content alloys
A Critical Review on Al-Co Alloys: Fabrication Routes, Microstructural Evolution and Properties
Al-Co alloys is an emerging category of metallic materials with promising properties and potential application in various demanding environments. Over the years, different manufacturing techniques have been employed to fabricate Al-Co alloys, spanning from conventional casting to rapid solidification techniques, such as melt spinning, thus leading to a variety of different microstructural features. The effect of the fabrication method on the microstructure is crucial, affecting the morphology and volume of the precipitates, the formation of supersaturated solid solutions and the development of amorphous phases. In addition, the alloy composition has an effect on the type and volume fraction of intermetallic phases formed. As a result, alloy properties are largely affected by the microstructural outcomes. This review focuses on highlighting the effect of the fabrication techniques and composition on the microstructure and properties of Al-Co alloys. Another goal is to highlight areas in the field that are not well understood. The advantages and limitations of this less common category of Al alloys are being discussed with the scope of future prospects and potential applications
Microstructure And Mechanical Properties Of Al-WC Composites
The scope of the research work is the production and characterization of Al matrix composites reinforced with WC ceramic nanoparticles. The synthesis process was powder metallurgy. The produced composites were examined as far as their microstructure and mechanical properties (resistance to wear, micro/macrohardness). Intermetallic phases (Al12W and Al2Cu) were identified in the microstrucutre. Al4C3 was not detected in the composites. Adding more than 5 wt% WC to the aluminum, microhardness and wear resistance exceed the values of Al alloy. Composites having weak interface bond performed the highest wear rate
No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
Background Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8–13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05–6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50–75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron
Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life
Call handling and mobility management in wireless ATM networks
Available from British Library Document Supply Centre-DSC:DXN028608 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo
Call handling and mobility management in wireless ATM networks
Available from British Library Document Supply Centre-DSC:DXN028608 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo
Notes on Consolida arenaria Carlström (Ranunculaceae). In Greuter, W. & Raus, Th. (eds.): Med-Checklist Notulae 21
- …